Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 25, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on May 22, 2006, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 17,827 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on May 24, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held in the GSK Trust in the same capacity as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Checklist
- Verify the total number of shares transferred (17,827) and the date of transfer (May 22, 2006).
- Confirm the specific employee share option plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Review the roles of the directors mentioned (Dr J-P Garnier, Dr T Yamada, Mr J S Heslop) regarding their interest in the GSK Trust.
- Check subsequent filings for any broader financial performance data, as this 6-K does not contain financial statements.